ERBB2 and neoplasm: The tumor inhibitory rate of the HER2-LsbMDDs was 88.9%, whereas they were 85.8, 78.4, and 80.1% for Tynen®, LsbMDDs, and DNS-LsbMDDs, respectively (Figure 5(D)).